Literature DB >> 1634807

Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group.

R W Pinner1, F Onyango, B A Perkins, N B Mirza, D M Ngacha, M Reeves, W DeWitt, E Njeru, N N Agata, C V Broome.   

Abstract

An epidemic of meningococcal disease occurred in Nairobi, Kenya, during 1989, outside the "meningitis belt" of sub-Saharan Africa. About 3800 cases occurred between April and November (250/100,000 population). The case-fatality rate was 9.4% among hospitalized patients. Areas that included Nairobi's largest slums had particularly high attack rates. The epidemic displayed an unusual age distribution, with high attack rates among those 20-29 years old. A vaccination campaign was conducted. By early January, the weekly case count had fallen to 25 from a high of 272 (in September). A case-control study estimated the vaccine efficacy to be 87% (95% confidence interval, 67%-95%). A model estimated that the vaccination campaign reduced the number of cases by at least 20%. Multilocus enzyme electrophoretic typing demonstrated that the strain responsible for this large epidemic is closely related to strains that caused other recent epidemics, documenting further spread of what may be a particularly virulent clonal complex of group A Neisseria meningitidis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1634807     DOI: 10.1093/infdis/166.2.359

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.

Authors:  Idris Mohammed; Garba Iliyasu; Abdulrazaq Garba Habib
Journal:  Pathog Glob Health       Date:  2017-01-12       Impact factor: 2.894

2.  Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.

Authors:  Ana Cristina C Frota; Lucimar G Milagres; Lee H Harrison; Bianca Ferreira; Daniela Menna Barreto; Gisele S Pereira; Aline C Cruz; Wania Pereira-Manfro; Ricardo Hugo de Oliveira; Thalita F Abreu; Cristina B Hofer
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

3.  Priority during a meningitis epidemic: vaccination or treatment?

Authors:  H Veeken; K Ritmeijer; B Hausman
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

4.  Time is (still) of the essence: quantifying the impact of emergency meningitis vaccination response in Katsina State, Nigeria.

Authors:  Matthew J Ferrari; Florence Fermon; Fabienne Nackers; Augusto Llosa; Claire Magone; Rebecca F Grais
Journal:  Int Health       Date:  2014-09-05       Impact factor: 2.473

5.  Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94.

Authors:  M Guibourdenche; E A Høiby; J Y Riou; F Varaine; C Joguet; D A Caugant
Journal:  Epidemiol Infect       Date:  1996-04       Impact factor: 2.451

6.  A tissue culture bilayer model to study the passage of Neisseria meningitidis.

Authors:  K A Birkness; B L Swisher; E H White; E G Long; E P Ewing; F D Quinn
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

7.  Characterization of the gene cassette required for biosynthesis of the (alpha1-->6)-linked N-acetyl-D-mannosamine-1-phosphate capsule of serogroup A Neisseria meningitidis.

Authors:  J S Swartley; L J Liu; Y K Miller; L E Martin; S Edupuganti; D S Stephens
Journal:  J Bacteriol       Date:  1998-03       Impact factor: 3.490

8.  A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995.

Authors:  J Y Riou; S Djibo; L Sangare; J P Lombart; P Fagot; J P Chippaux; M Guibourdenche
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

Review 9.  Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.

Authors:  Mark A Miller; Cathryn K Shahab
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

Authors:  E L Anderson; T Bowers; C M Mink; D J Kennedy; R B Belshe; H Harakeh; L Pais; P Holder; G M Carlone
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.